Semnur Pharmaceuticals, Inc. (SMNR)
OTCMKTS · Delayed Price · Currency is USD
9.00
-10.00 (-52.63%)
At close: Oct 1, 2025
Semnur Pharmaceuticals Company Description
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP.
The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Semnur Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Pharmaceutical Preparations |
| Employees | 1 |
| CEO | Jaisim Shah |
Contact Details
Address: 960 San Antonio Road Palo Alto, Delaware 94303 United States | |
| Phone | 650 516 4310 |
| Website | semnurpharma.com |
Stock Details
| Ticker Symbol | SMNR |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jaisim Shah | Chief Executive Officer |
| Stephen Ma | Chief Financial Officer |